Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 3, 2006, Pages 214-218

  Azuma, Mizutomo ^a,d   Danenberg, Kathleen D ^b   Iqbal, Syma ^a   El Khoueiry, Anthony ^a   Zhang, Wu ^a   Yang, Dongyun ^c   Koizumi, Wasaburo ^d   Saigenji, Katsunori ^d   Danenberg, Peter V ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Response Genetics Inc   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Complementary DNA; Microdissection; Real time polymerase chain reaction; RNA isolation

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT TYPE 3; MESSENGER RNA; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER MICRODISSECTION; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

EID: 33750189788     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.038     Document Type: Article

References (33)

1. Thompson DM and Gill GN. The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv 1985; 4:767-788.
2. Sainsbury JR, Farndon JR, Needham GK, et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1:1398-1402.
3. Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996; 73:301-306.
4. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47:707-712.
5. Ozanne B, Richards CS, Hendler F, et al. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986; 149:9-14.
6. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94:1593-1611.
7. Korshunov A, Golanov A, Sycheva R, et al. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 1999; 52:574-580.
8. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-832.
9. Klijn JG, Berns PM, Schmitz PI, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13:3-17.
10. Hemming AW, Davis NL, Kluftinger A, et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51:147-152.
11. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
12. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
13. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992; 89:2965-2969.
14. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55:5536-5539.
15. Olapade-Olaopa EO, Moscatello DK, MacKay EH, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000; 82:186-194.
16. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53:3217-3220.
17. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992; 89:4309-4313.
18. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55:3140-3148.
19. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002; 98:357-361.
20. Cunningham MP, Essapen S, Thomas H, et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005; 27:317-325.
21. Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997; 278:1481-1483.
22. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4:135-142.
23. Rae JM, Scheys JO, Clark KM, et al. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 2004; 87:87-95.
24. Chu CT, Everiss KD, Wikstrand CJ, et al. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997; 324:855-861.
25. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995; 6:1251-1259.
26. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994; 91:7727-7731.
27. Prigent SA, Nagane M, Lin H, et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996; 271:25639-25645.
28. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272:2927-2935.
29. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60(suppl 1):33-40; discussion, 41-42. Review.
30. Lichtner RB, Menrad A, Sommer A, et al. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001; 61:5790-5795.
31. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7:1459-1465.
32. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
33. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3496-3502.